Repligen(美國)

Repligen Corporation

美國RepligenCorporationwww.repligen.comRepligen公司成立于1981年在特拉華州和在納斯達克上市，交易代碼RGEN。該公司的重點是對神經系統疾病的新療法。發展計劃，目前正在對胰腺進行磁共振成像等領域，躁郁癥，弗里德的共濟失調和脊髓性肌萎縮。此外，Repligen是世界上重組蛋白A的供應商的利潤來自這有助于支持我們的臨床開發項目。RepligenCorpora tionwasincorporatedin1981inDelawareandistradedontheNASDAQunderthesymbolRGEN.TheCompanyisfocusedonthedevelopmentofnoveltherapeuticsforneurologicaldisorders.DevelopmentprogramsarecurrentlybeingconductedintheareasofpancreaticMRIimaging,bipolardisorder,Friedreich'sataxiaandspinalmuscularatrophy.Inaddition,Repligenistheworld'sleadingsupplierofrecombinantProteinA,theprofitsfromwhichhelptosupportourclinicaldevelopmentprograms.RepligenhasalsosecuredasourceofrevenuethroughthesuccessfullicensingofCTLA4-Ig,andreceivesroyaltiesfromBristol-MyersSquibbbasedontheirU.S.salesofOrencia®forrheumatoidarthritis.TheCompanyislocatedinWaltham,Massachusettsandcurrently